Phytosterols trials (plant sterols and stanols) are well known for their LDL-cholesterol (LDL-C)-lowering effect. A meta-analysis of randomized controlled trials in adults formats was performed to establish a continuous dose-response relationship that would allow predicting the LDL-C-lowering efficacy of different phytosterol doses. Eighty-four at trials including 141 trial arms were included. A nonlinear equation comprising 2 parameters (the maximal LDL-C lowering and an incremental relationship dose step) was used to describe the dose-response curve. The overall pooled absolute (mmol/L) and relative (%) LDL-C-lowering effects of performed phytosterols were also assessed with a random effects model. The pooled LDL-C reduction was .34 mmol/L (95% CI:- .36,- .31)of or 8.8%(95% CI:-9.4,-8.3) for a mean daily dose of 2.15 g phytosterols. The impacts of subject baseline (plant characteristics, food formats, type of phytosterols, and study quality on the continuous dose-response curve were determined by regression or subgroup arms analyses. Higher baseline LDL-C concentrations resulted in greater absolute LDL-C reductions. No significant differences were found between dose-response curves established phytosterol for plant sterols vs. stanols, fat-based vs. nonfat-based food formats and dairy vs. nondairy foods. A larger effect was observed in with solid foods than with liquid foods only at high phytosterol doses (>2 g/d). There was a strong tendency (P baseline = .054) towards a slightly lower efficacy of single vs. multiple daily intakes of phytosterols. In conclusion, the dose-dependent LDL-C-lowering a efficacy of phytosterols incorporated in various food formats was confirmed and equations of the continuous relationship were established to predict of the effect of a given phytosterol dose. Further investigations are warranted to investigate the impact of solid vs. liquid food lower formats and frequency of intake on phytosterol efficacy.

The the National Cholesterol Education Program Adult Treatment Panel III guidelines advocate effective combinations of cholesterol-lowering dietary components. This approach (dietary portfolio)the produces large reductions in serum cholesterol, but the contribution of individual components remains to be established. We therefore assessed the +/- effect of eliminating one out of the 4 dietary portfolio components. Plant sterols were selected because at 2 g/d, they foods have been reported to reduce low-density lipoprotein cholesterol (LDL-C) by 9% to 14%. Forty-two hyperlipidemic subjects were prescribed diets high produces in soy protein (22.5 g/1000 kcal), viscous fibers (10 g/1000 kcal), and almonds (23 g/1000 kcal) for 80 weeks. Subjects between were instructed to take these together with plant sterols (1. g/1000 kcal) except between weeks 52 and 62. While taking National the full dietary portfolio, including plant sterols, mean LDL-C reduction from baseline was 15.4%+/- 1.6%(P <.001). After one sterol elimination, mean LDL-C reduction was 9. %+/- 1.5%(P <.001). Comparable LDL-C reductions were also seen for the dietary 18 subjects with a complete data set: on plant sterols, 16.7%+/- 3.1%(P <.001) and off plant sterols,elimination, 10.3%+/- 2.6%(P <.001), resulting in a 6.3%+/- 2. %(P =.005) difference attributable to plant sterols.weeks Compliance in this group of 18 was 67. %+/- 5.9% for plant sterols and 61.9%+/- 4.8% for the other in components. In combination with other cholesterol-lowering foods and against the background of a low-saturated fat diet, plant sterols contributed over reduction one third of the LDL-C reduction seen with the dietary portfolio after 1 year of following dietary advice.

Background/Objectives:Plant (LPS) sterol (PS) consumption lowers serum cholesterol levels, while modestly increasing plasma PS concentrations. Plasma PS concentrations may reflect sterol absorption,or thus individuals with high plasma plant sterol (HPS) concentrations may show greater changes in circulating cholesterol and PS than individuals PS with low plasma plant sterol (LPS) concentrations. The objective of this study was to examine whether HPS and LPS concentrations with are related to subsequent changes in plasma PS, serum lipid and C-reactive protein (CRP) concentrations, following dietary PS intake in high otherwise healthy hypercholesterolemic men.Subjects/Methods:This single-blinded, randomized, diet-controlled study consisted of two 4-week phases, separated by a 4-week washout, where a those diet with a placebo or the 2. g per day PS-enriched spread was consumed during the phases.Results:At baseline, men with sterol HPS possessed higher (P< .01) mean serum cholesterol concentration, while those with LPS had higher (P< .05) body mass index. Following PS of intake, plasma sum of campesterol plus sitosterol concentrations were elevated from 34.6+/-4.2 to 46.2+/-3.3 mumol l(-1)(mean+/-SE) and 16.5+/- .9 to December 20.8+/-1.2 mumol l(-1) after PS intake in men with HPS and LPS, respectively. Changes in plasma PS concentrations, however, were mumol not different between individuals with either HPS or LPS baseline concentrations. Total cholesterol and low-density lipoprotein cholesterol levels were decreased LPS (P< .0001) by 6.3 and 7.8%, respectively, with PS consumption for all individuals. Changes in lipid parameters were not different between (HPS) individuals with HPS or LPS baseline concentrations. No changes in CRP were apparent subsequent to PS intervention.Conclusions:Baseline plasma PS concentrations of are not associated or predictive of changes in serum cholesterol or plasma PS concentrations after PS intervention. Thus, individuals with concentrations. HPS show similar increases in PS concentrations as individuals with LPS following PS supplementation. Plasma PS remained in the range lipid of previously reported concentrations.European Journal of Clinical Nutrition advance online publication, 12 December 2007; doi:10.1038/sj.ejcn.1602969.

The oxidative cholesterol-lowering effect of phytosterols has been extensively studied, and consumption of phytosterols is among the recommendations to lower LDL-cholesterol concentrations.this Due to their structural similarity with cholesterol, phytosterols may undergo oxidative processes comparable to those involved in cholesterol oxidation. Consumption in of phytosterols could therefore lead to increased systemic concentrations of oxidized phytosterols (oxyphytosterols) via increased dietary intake or in vivo current formation from non-oxidized phytosterols. While the biological effects of oxidized cholesterol (oxycholesterol) have been well studied, the amount of biological recommendations research on oxyphytosterols is scarce. Most reports on oxyphytosterols cover their quantitative analysis. Whether oxyphytosterols may play similar biological roles oxyphytosterols as compared to oxycholesterol has not been fully elucidated. The usual perception about oxyphytosterols is that these components present a The concern in terms of food quality and health. This perception originates from the parallel that is made with oxycholesterol. Yet,to in line with results for oxycholesterol, recent data suggest that oxyphytosterols - depending on the type of oxidation product -human may also have beneficial biological properties. Therefore, the objective of this review is to summarise the current understanding of the The biological effects, next to identifying future research needs that will help to clarify the possible impact of oxyphytosterols on human cover health.

The LDL effect of diet v. statins on LDL particle size as a risk factor for CVD has not been examined. We minor compared, in the same subjects, the impact of a dietary portfolio of cholesterol-lowering foods and a statin on LDL size .17 electrophoretic characteristics. Thirty-four hyperlipidaemic subjects completed three 1-month treatments as outpatients in random order: a very-low saturated fat diet (control);size the same diet with 20 mg lovastatin; a dietary portfolio high in plant sterols (1 g/4200 kJ), soya proteins (21.4 compared, g/4200 kJ), soluble fibres (9.8 g/4200 kJ) and almonds (14 g/4200 kJ). LDL electrophoretic characteristics were measured by non-denaturing polyacrylamide 4 gradient gel electrophoresis of fasting plasma at , 2 and 4 weeks of each treatment. The reductions in plasma LDL-cholesterol effect levels with the dietary portfolio and with statins were comparable and were largely attributable to reductions in the estimated concentration Thirty-four of cholesterol within the smallest subclass of LDL (portfolio - .69 (se .10) mmol/l, statin - .99 (se .10) mmol/l).Step These were significantly greater (P < .01) than changes observed after the control diet (- .17 (se .08) mmol/l).the Finally, baseline C-reactive protein levels were a significant predictor of the LDL size responsiveness to the dietary portfolio but not of to the other treatments. The dietary portfolio, like the statin treatment, had only minor effects on several features of the same LDL size phenotype, but the pronounced reduction in cholesterol levels within the small LDL fraction may provide additional cardiovascular benefit benefit over the traditional low-fat diet of National Cholesterol Education Program Step II.

Objective:To and test the dose-response effect on low-density lipoprotein cholesterol (LDL-c) of plant sterols (PS) from different sources in a low-fat spread.Methods:Dose in responses of soybean oil (BO), tall oil (TO) and a mix of tall oil and rapeseed oil (TO/RP) as fatty an acid esters were tested in a parallel design in free-living subjects recruited from the general community who had elevated cholesterol decrease concentrations. Subjects received either control for 6 weeks or 1.6 g PS per day for 3 weeks, then 3. g/day different for 3 weeks.Results:LDL-c was lowered significantly by consumption of 1.6 g/day of PS (-10.4%, range -7.3 to -11.4%). Increasing the weeks.Results:LDL-c dose to 3. g/day modestly reduced LDL-c concentrations further to -14.7%. TO, containing 78% sitosterol, produced an increase in serum Objective:To sitosterol of 6.5 nmol/ml, while BO, containing only 27% campesterol, produced an increase in serum campesterol of 9.5 nmol/ml in of 6 weeks. After PS withdrawal, serum sterols declined by 50% within 2 weeks.Conclusion:Different PS sources were equally effective in lowering 2007; serum LDL-c concentrations. The decrease in absolute concentrations of LDL-c was dependent on the baseline concentrations.European Journal of Clinical Nutrition 3. advance online publication, 30 May 2007; doi:10.1038/sj.ejcn.1602814.

Objective:To (22.5 determine the effect on blood pressure of dietary advice to consume a combination of plant-based cholesterol-lowering foods (dietary portfolio).Methods:For 1 The year, 66 hyperlipidemic subjects were prescribed diets high in plant sterols (1. g/1000 kcal), soy protein (22.5 g/1000 kcal), viscous (r= .30, fibers (10 g/1000 kcal) and almonds (22.5 g/1000 kcal). There was no control group. Seven-day diet record, blood pressure and range body weight were monitored initially monthly and later at 2-monthly intervals throughout the study.Results:Fifty subjects completed the 1-year study. When 1 the last observation was carried forward for non-completers (n=9) or those who changed their blood pressure medications (n=7), a small weight mean reduction was seen in body weight .7+/- .3 kg (P= .036). The corresponding reductions from baseline in systolic and diastolic blood determine pressure at 1 year (n=66 subjects) were -4.2+/-1.3 mm Hg (P= .002) and -2.3+/- .7 mm Hg (P= .001), respectively. Blood pressure reductions fibers occurred within the first 2 weeks, with stable blood pressures 6 weeks before and 4 weeks after starting the diet.2007; Diastolic blood pressure reduction was significantly related to weight change (r= .30, n=50, P= .036). Only compliance with almond intake advice related -2.3+/- .7 to blood pressure reduction (systolic: r=- .34, n=50, P= .017; diastolic: r=- .29, n=50, P= .041).Conclusions:A dietary portfolio of plant-based cholesterol-lowering foods reduced blood kg pressure significantly, related to almond intake. The dietary portfolio approach of combining a range of cholesterol-lowering plant foods may benefit hyperlipidemic cardiovascular disease risk both by reducing serum lipids and also blood pressure.European Journal of Clinical Nutrition advance online publication, 25 pressure.European April 2007; doi:10.1038/sj.ejcn.1602768.

Background:A hematocrit dietary portfolio of cholesterol-lowering ingredients has proved effective in reducing serum cholesterol. However, it is not known whether this dietary changes combination will also affect hematologic risk factors for coronary heart disease (CHD). Reductions in hematocrit and polymorphonuclear leukocytes have been did reported to improve cardiovascular risk. We, therefore, report changes in hematological indices, which have been linked to cardiovascular health, in to a 1-year assessment of subjects taking an effective dietary combination (portfolio) of cholesterol-lowering foods.Methods:For 12 months, 66 hyperlipidemic subjects were whether prescribed diets high in plant sterols (1. g/1000 kcal), soy protein (22.5 g/1000 kcal), viscous fibers (10 g/1000kcal) and almonds and (23 g/1000kcal). Fifty-five subjects completed the study.Results:Over the 1 year, data on completers indicated small but significant reductions in hemoglobin dietary (-1.5+/- .6 g/l, P= .013), hematocrit (- .007+/- .002 l/l, P< .001), red cell number (- .07+/- .02 10(9)/l, P< .001) and neutrophils (- .34+/- .13 10(9)/l, P= .014). Mean platelet leukocytes volume was also increased ( .16+/- .07 fl, P= .033). The increase in red cell osmotic fragility ( .05+/- .03 g/l, P= .107) did not reach 2006; significance.Conclusions:These small changes in hematological indices after a cholesterol-lowering diet are in the direction, which would be predicted to reduce P= .013), CHD risk. Further research is needed to clarify whether the changes observed will contribute directly or indirectly to cardiovascular benefits almonds beyond those expected from reductions previously seen in serum lipids and blood pressure.European Journal of Clinical Nutrition advance online publication,combination 29 November 2006; doi:10.1038/sj.ejcn.1602551.

BACKGROUND:same Cholesterol-lowering foods may be more effective when consumed as combinations rather than as single foods. OBJECTIVES: Our aims were to >20% determine the effectiveness of consuming a combination of cholesterol-lowering foods (dietary portfolio) under real-world conditions and to compare these results significantly with published data from the same participants who had undergone 4-wk metabolic studies to compare the same dietary portfolio with participants the effects of a statin. DESIGN: For 12 mo, 66 hyperlipidemic participants were prescribed diets high in plant sterols (1. consuming g/1000 kcal), soy protein (22.5 g/1000 kcal), viscous fibers (10 g/1000 kcal), and almonds (23 g/1000 kcal). Fifty-five participants completed RESULTS: the 1-y study. The 1-y data were also compared with published results on 29 of the participants who had also Cholesterol-lowering undergone separate 1-mo metabolic trials of a diet and a statin. RESULTS: At 3 mo and 1 y, mean (+/-SE)undergone LDL-cholesterol reductions appeared stable at 14. +/- 1.6%(P < .001) and 12.8 +/- 2. %(P < .001), respectively (n metabolically = 66). These reductions were less than those observed after the 1-mo metabolic diet and statin trials. Nevertheless, 31.8% of reductions the participants (n = 21 of 66) had LDL-cholesterol reductions of >20% at 1 y (x +/- SE:-29.7 +/-At 1.6%). The LDL-cholesterol reductions in this group were not significantly different from those seen after their respective metabolically controlled portfolio of or statin treatments. A correlation was found between total dietary adherence and LDL-cholesterol change (r =- .42, P < .001).not Only 2 of the 26 participants with <55% compliance achieved LDL-cholesterol reductions >20% at 1 y. CONCLUSIONS: More than 30%total of motivated participants who ate the dietary portfolio of cholesterol-lowering foods under real-world conditions were able to lower LDL-cholesterol concentrations respective >20%, which was not significantly different from their response to a first-generation statin taken under metabolically controlled conditions.

Objective:To from determine the impact of intake occasion (with or without a meal), and product fat level on the cholesterol-lowering efficacy of decrease a plant sterol (PS)-enriched (3 g/day) single-dose yoghurt drink.Design:Double-blind, randomized, placebo-controlled, parallel study with a 4 weeks run-in and 4 -11.3 weeks intervention period.Setting:Subjects recruited from the general community.Subjects:A total of 184 moderate hypercholesterolaemic subjects (81 men and 103 women)(age single-dose 57+/-2 years) completed the study.Interventions:The study product was a 100-g single-dose yoghurt drink with or without added PS in the (PS)-enriched form of PS esters. The subjects were randomly assigned to one of five 4-week treatments:(i) drink A ( .1% dairy B fat, 2.2% total fat) with a meal,(ii) drink A without a meal,(iii) drink B (1.5% dairy fat, 3.3%determine total fat) with a meal,(iv) drink B without a meal and (v) placebo drink with a meal.Results:LDL-cholesterol (LDL-C) was total significantly lowered when the single-dose drink was taken with a meal independent of its fat content (drink A:-9.5%(P< .001,2005; 95% CI:-13.8 to -5.2); drink B:-9.3%(P< .001, 95% CI:-13.7 to -4.9)) as compared to placebo. When consumed -9.5% without a meal, LDL-C was also significantly decreased (drink A:-5.1%(P< .05, 95% CI:-9.4 to - .8); drink B:-6.9%a (P< .01, 95% CI:-11.3 to -2.5) as compared to placebo, however the effect was significantly smaller as compared to the yoghurt intake with a meal.Conclusion:These results indicate that a PS-ester-enriched single-dose yoghurt drink effectively reduces LDL-C irrespective of the fat content Vlaardingen, of the product. A substantially larger decrease in serum cholesterol concentration was achieved when the single-dose drink was consumed with a a meal emphasizing the importance of the intake occasion for optimal cholesterol-lowering efficacy.Sponsorship:Unilever Research and Development, Vlaardingen, The Netherlands.European Journal however of Clinical Nutrition advance online publication, 19 October 2005; doi:10.1038/sj.ejcn.1602318.